Table 2.
Clinicopathological features of the patients and correlation of SALL4 gene expression with them
| Factor | Number (%) |
SALL4 |
P value | |
|---|---|---|---|---|
| ↑ | ↓ / - | |||
|
Tumor invasion |
|
|||
|
T1, T2 |
8 (17.4%) |
8 |
0 |
0.538 |
|
T3, T4 |
38 (82.6%) |
32 |
6 |
|
|
Lymph node metastasis |
|
|||
|
N0 |
33 (71.7%) |
28 |
5 |
0.047* |
|
N1 |
9 (19.6%) |
9 |
0 |
|
|
N2 |
4 (8.7) |
3 |
1 |
|
|
Stage |
|
|||
|
I/II |
34 (73.9%) |
29 |
5 |
0.397 |
|
III/IV |
12 (26.1%) |
11 |
1 |
|
|
Grade |
|
|||
|
WD |
29 (63%) |
25 |
4 |
0.020* |
|
MD |
16 (34.8%) |
15 |
1 |
|
|
PD |
1 (2.2%) |
0 |
1 |
|
|
Tumor location |
|
|||
|
Proximal |
13 (28.3%) |
11 |
2 |
0.611 |
|
Distal |
33 (71.7%) |
29 |
4 |
|
|
Sex |
|
|||
|
Male |
26 (56.5%) |
22 |
4 |
0.030* |
| Female | 20 (43.5%) | 18 | 2 | |
WD: Well differentiated; MD: Moderately differentiated; PD: Poorly differentiated.
*Significant correlation between SALL4 mRNA expression and clinicopathological feature.